{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:26:02Z","timestamp":1792887962520,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jpeds.2020.08.088","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T12:10:07Z","timestamp":1599048607000},"page":"38-45.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1597-7482","authenticated-orcid":false,"given":"Emma","family":"Greenaway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2020.08.088_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciu447","article-title":"Vertical transmission of hepatitis C virus: systematic review and meta-analysis","volume":"59","author":"Benova","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpeds.2020.08.088_bib2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jpeds.2013.06.077","article-title":"Perinatal transmission of hepatitis C virus","volume":"163","author":"Indolfi","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2468-1253(19)30385-1","article-title":"Global prevalence of hepatitis C virus in children in 2018: a modelling study","volume":"5","author":"Schmelzer","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2020.08.088_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00043426-200111000-00012","article-title":"Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer","volume":"23","author":"Strickland","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jpeds.2020.08.088_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpeds.2006.11.037","article-title":"Clinical spectrum and histopathologic features of chronic hepatitis C infection in children","volume":"150","author":"Mohan","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MPG.0b013e318170af04","article-title":"Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C","volume":"48","author":"Gonzalez-Peralta","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1746.2007.04859.x","article-title":"Health-related quality of life in children with hepatitis C acquired in the first year of life","volume":"23","author":"Nydegger","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2020.08.088_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","article-title":"Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes","volume":"48","author":"Rodrigue","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib10","doi-asserted-by":"crossref","first-page":"e027491","DOI":"10.1136\/bmjopen-2018-027491","article-title":"Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update","volume":"9","author":"Erman","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpeds.2020.08.088_bib11","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2020.08.088_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0272989X03261568","article-title":"Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990","volume":"24","author":"Krahn","year":"2004","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jpeds.2020.08.088_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jpeds.2020.08.088_bib14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpeds.2020.08.088_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.510280333","article-title":"Predictors of patient and graft survival following liver transplantation for hepatitis C","volume":"28","author":"Charlton","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","article-title":"A systematic review and meta-analysis of health utilities in patients with chronic hepatitis C","volume":"23","author":"Saeed","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jpeds.2020.08.088_bib17","author":"Haines"},{"key":"10.1016\/j.jpeds.2020.08.088_bib18","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MPG.0b013e3181d32756","article-title":"Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection","volume":"51","author":"Delgado-Borrego","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib22","series-title":"Decision making in health and medicine: integrating evidence and values","author":"Hunink","year":"2014"},{"key":"10.1016\/j.jpeds.2020.08.088_bib23","doi-asserted-by":"crossref","first-page":"e0201120","DOI":"10.1371\/journal.pone.0201120","article-title":"Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study","volume":"13","author":"Lapointe-Shaw","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jpeds.2020.08.088_bib25","author":"Wodchis"},{"key":"10.1016\/j.jpeds.2020.08.088_bib26","doi-asserted-by":"crossref","first-page":"E617","DOI":"10.1503\/cmaj.1095412","article-title":"Secrecy on cost of publicly funded hep C treatment","volume":"189","author":"Webster","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.jpeds.2020.08.088_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.08.088_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpeds.2018.12.012","article-title":"Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection","volume":"207","author":"Nguyen","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2020.08.088_bib30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.08.088_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620311240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620311240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:08:32Z","timestamp":1758359312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347620311240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"alternative-id":["S0022347620311240"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.08.088","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.08.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.10.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}